CAR, was shown to be safe, with increasing efficacy corresponding to higher doses of the investigational treatment in nine ...

Eli Lilly and Company and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire ...

Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American ...

An update on CAR-T therapies for MM and B-cell NHL presented at the 2026 ONA Summit highlighted the integral role of oncology nurses in ensuring patients achieve optimal outcomes.

Researchers are advancing CAR T-cell therapy for solid tumors using armored cells that deliver IL-36γ. Expanded manufacturing ...

Invariant natural killer T cells have emerged as a potentially versatile allogeneic platform for blood cancer immunotherapy, ...

You will be redirected to our submission process. Microbial dysbiosis has emerged as a central factor influencing host susceptibility to infection and the development of systemic immune dysfunction.

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...

T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on exquisitely timed molecular signals. Now researchers have captured one of the ...

The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has developed a new class of engineered extracellular vesicles (EVs) capable of ...